Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.
Altimmune Capex-to-Operating-Income Historical Data
The historical data trend for Altimmune's Capex-to-Operating-Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Altimmune's Capex-to-Operating-Income
For the Biotechnology subindustry, Altimmune's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Altimmune's Capex-to-Operating-Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Altimmune's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where Altimmune's Capex-to-Operating-Income falls into.
Altimmune Capex-to-Operating-Income Calculation
Altimmune's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
Altimmune Capex-to-Operating-Income Related Terms
Thank you for viewing the detailed overview of Altimmune's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company's pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALT has been successfully added to your 